A series of 4-nitroimidazole derivatives bearing substituted piperazines (5, 8, 9, 12, 14, 16, 17, and 19 -21) were synthesized with the aim to develop new non-nucleoside reverse transcriptase inhibitors (NNRTIs). The newly synthesized compounds were assayed against HIV-1 and HIV-2 in MT-4 cells. All compounds are inactive, except compound 21 which showed inhibition of HIV-1 with EC 50 0.20 µg/mL, and therapeutic indexes (SI) of 12.
Introduction
Nitro-substituted haloimidazoles are considered as compounds with important biological activity as antibacterial agents [1, 2] , potential radiosensitizers [3] and anticancer agents [4, 5] . Dacarbazine ® (DTIC) [6] is synthesized as an alkylating agent for inhibition of de novo purine synthesis, while misonidazole 1 [7] has been reported as a potential anticancer agent. Other imidazole derivatives, such as clotrinazole [1-(2-chlorotrityl)-1H-imidazole] [8, 9] and metronidazole (Flagyl) 2 [10] , have been considered as potent fungicides and/or used as antiprotozoal agents (especially for treatment of Trichomonas vaginalis, Entamoeba histolytica and Giardia lamblia). Capravirine, (S-1153, 3) is an imidazole analogue with a high anti-HIV inhibitory activity [11] .
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The facile replacement of the halogen substituent in the nitro-substituted haloimidazoles prompted many laboratories [12 -18] to develop new high-yield syntheses leading to interesting imidazole compounds bearing various alkylsulfanyl or alkylamino groups via nucleophilic substitution of the halogen by N or S nucleophiles. With the potential biological activity in mind, we synthesized new substituted 4-nitroimidazoles and evaluated their HIV activity.
Results
Our recent work [19, 20] has focused on the substitution of the bromo group of 5-bromo-1-benzyl-2-ethyl-4-nitroimidazole 4 [18] by various primary and secondary amines as well as by alkylsulfanyl precursors [13] to furnish potentially active analogues. In the present work, compound 4 has been selected as start- Scheme 1. ing material for the synthesis of new substituted imidazole compounds via the nucleophilic displacement of the bromine group activated by an adjacent nitro function. Treatment of 4 with piperazine in DMF afforded 5 (72 %), which gave 8 and 9 in 34 and 31 % yield, respectively, on reaction with 2-chlorobenzoxazole (6) and 2-chlorobenzothiazole (7), respectively, in the presence of NaH/DMF.
On the other hand, treatment of 5 with the 4-(1,2,4-triazol-3-yl)benzyl chloride derivatives [21] 10 and 11 afforded, after purification, compounds 12 and 13 in 64 and 38 % yield, respectively.
Treatment of 4 with piperazine-1-carbaldehyde in DMF afforded after chromatographic purification compound 14 (87 %) (Scheme 1).
The structures of 5 and 8 -14 were identified by heteronuclear NMR spectroscopic methods including HMBC spectra [22] and mass spectra. The 1 H NMR spectra of 5, 8, 9 and 12 -14 showed rather similar patterns. The resonances of the piperazine moiety appeared as two broad singlets at δ = 3.89 -2.65 and δ = 3.51 -2.56, the signal of the benzylic protons at δ = 5.24 -5.16. The aldehyde proton of 14 gave a singlet at δ = 8.67. The 13 C NMR spectra of 8 and 9 contained high-field signals at δ = 160.8 and 167.9 which were attributed to C-10 of the oxazole and thiazole rings, respectively. Carbon atom C-2 of the imidazole ring resonated at δ = 140.0. The piperazine carbon atoms were identified at δ = 48.4 and 46.4. Carbon atoms C-4 and C-5 of the imidazole ring gave signals at δ = 137.7 and 135.4. The 13 C NMR spectra of 12 and 13 were similar to those of the analogues 8 and 9. The carbon atoms of the triazole ring were assigned to the signals at δ = 159.5 and 152.3 for 8 and δ = 152.2 and 145.1 for 9.
Next, our efforts have been focused on the Nalkylation of 2-methyl-4-nitroimidazole (15) by introduction of potential alkyl groups. Thus, treatment of 15 with 6 or 7 and NaH in DMF afforded, after purification, compounds 16 and 17 in 41 and 46 % yield, respectively. A similar treatment of 15 with the benzylic chlorides 10, 11 or 18 gave N 1 -benzylimidazoles 19 -21 in 27, 38 and 40 % yield, respectively (Scheme 2). The constitution of 16, 17 and 19 -21 was derived from their NMR ( 1 H, 13 C) and mass spectra. The HMBC spectrum of 21 showed 2 J C,H coupling be-
tween C-4 of the imidazole ring (δ = 136.4) and 5-H (δ = 8.46). 3 J C,H coupling was observed between C-4 and the methylene protons (CH 2 Ph) (δ = 5.32). 2 J C,H coupling was found between C-2' of the triazole ring (δ = 58.5) and 9'-H 2 (δ = 2.94), and 3 J C,H coupling between C-2' and 8'-H 2 (δ = 1.74). Table 1 , in which the data for efavirenz [23] and capravirine [11] are included for comparison purposes. Compound 21 was found to be the only compound in the series inhibiting HIV-1 replication in cell culture. Compound 21 showed an EC 50 of 0.20 µg/mL and a CC 50 of 2.40 µg/mL, resulting in a selectivity index of 12.
In vitro anti-HIV assay
Based on the chemical structure and the fact that compound 21 inhibits HIV-1, but not HIV-2 replication, this molecule can be proposed to act as an nonnucleoside reverse transcriptase inhibitor (NNRTI). This hypothesis was further confirmed by assaying the compound against a typical NNRTI-resistant HIV-1 strain (double mutation in RT: K103N and Y181C). Compound 21 completely lost its inhibitory activity against this resistant strain.
Experimental Section
Melting points were measured on a Büchi melting point apparatus B-545 (BÜCHI Labortechnik AG, Switzerland) without correction. 1 H and 13 C NMR spectra were measured on a UltraShield TM NMR-300 MHz Bruker instrument with TMS as internal standard and on the δ scale in ppm. Microanalytical data were obtained with a Vario Elementar apparatus. EI and FAB mass spectra were measured on a GC-MS Shimadzu QP-505A (Japan) spectrometer.
1-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)piperazine (5)
A solution of 4 (3.10 g, 10.0 mmol) in DMF (25 mL) and piperazine (1.03 g, 12.0 mmol) was stirred at 70 -80 • C for 6 h. After cooling the precipitation was filtered and recrystallized from EtOH to give 5 (2.27 g, 72 % 
2-[4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)piperazin-1-yl]benzoxazole (8)
To a solution of 5 (0.32 g, 1.0 mmol) in DMF (15 mL) containing NaH (1.0 mmol) was added a solution of 6 (0.15 g, 1.0 mmol) in DMF (5 mL) and the mixture was stirred at 23 • C for 48 h. The solvent was evaporated and the residue brought to dryness and partitioned between CH 2 Cl 2 (40 mL) and water (40 mL). The organic phase was dried (Na 2 SO 4 ), filtered and evaporated to dryness and the residue was purified by chromatography (10 g), using CH 2 Cl 2 -MeOH 
2-[4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)piperazin-1-yl]benzothiazole (9)
This compound was prepared from 5 (0.32, 1.0 mmol) and 7 (0.17 g, 1.0 mmol), by following the same procedure as for the preparation 8. Yield: 0.14 g (31 % 
1-[4-(1-Ethyl-5-methyl-1H-1,2,4-triazol-3-yl)benzyl-4-1-benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl]piperazine (12)
This compound was prepared from 5 (0.32, 1.0 mmol) and 10 (0.24 g, 1.0 mmol), analogously to the preparation of 8. 
2-[4-((4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)piperazin-1-yl)methyl)phenyl]-5,6,7,8-tetrahydro[1,2,4]-triazolo-[1,5-a]pyridine (13)
This compound was prepared from 5 (0.32, 1.0 mmol) and 11 (0.25 g, 1.0 mmol), by following the same procedure as for 8. Yield: 0.20 g (38 %). M. p. 148 -150 • C. 
4-(1-Benzyl-2-ethyl-4-nitro-1H-imidazol-5-yl)piperazin-1-carbaldehyde (14)
A solution of 5 (0.34 g, 3.0 mmol) in DMF (30 mL) containing piperazine-1-carbaldehyde (0.93 g, 3.0 mmol) was heated at 70 -80 • C for 6 h. After cooling overnight, the crystals were collected to give 14 (0.89 g, 87 %). M. p. 297 -299 • C. -4-nitro-1H-imidazol-1-yl) benzoxazole (16) To a solution of 15 (0.13 g, 1.0 mmol) in DMF (15 mL) containing NaH (1.0 mmol) was added a solution of 6 (0.15 g, 1.0 mmol) in DMF (5 mL) and the mixture was stirred at 120 -130 • C for 12 h. After cooling, the reaction mixture was worked up as described for 8. 
2-(2-Methyl

2-(2-Methyl-4-nitro-1H-imidazol-1-yl)benzothiazole (17)
This compound was prepared from 15 (0. 
1-Ethyl-5-methyl-3-[((2-methyl-4-nitro-1H-imidazol-1-yl)methyl)phenyl]-1H-1,2,4-triazole (19)
This compound was prepared from 15 (0.13 g, 1.0 mmol) and 10 (0.24 g, 1.0 mmol), by following the same procedure as for 8. Yield: 0.09 g (27 %). M. p. 166 -168 • C. 
6,7,8,9-Tetrahydro-2-[4-((2-methyl-4-nitro-1H-imidazol-1-yl-)methyl)phenyl]-5H-[1,2,4]-triazolo[1,5-a]azepine (21)
